Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free ACB Stock Alerts

Aurora Cannabis (ACB) Competitors

Aurora Cannabis logo
C$5.94 -0.06 (-1.00%)
As of 09/23/2026 04:00 PM Eastern
Compare

ACB vs. DHT.UN, GUD, THCX, TLRY, and CMED

Should you buy Aurora Cannabis stock or one of its competitors? Aurora Cannabis's main competitors and comparable companies include DRI Healthcare Trust (DHT.UN), Knight Therapeutics (GUD), Hydropothecary (THCX), Tilray Brands (TLRY), and CanniMed Therapeutics (CMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aurora Cannabis compare to DRI Healthcare Trust?

Aurora Cannabis (TSE:ACB) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

DRI Healthcare Trust has lower revenue, but higher earnings than Aurora Cannabis. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M1.17-C$44.16M-C$1.94N/A
DRI Healthcare TrustC$172.34M5.79C$9.73M-C$0.80N/A

In the previous week, DRI Healthcare Trust had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 4 mentions for DRI Healthcare Trust and 3 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.73 beat DRI Healthcare Trust's score of 0.51 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DRI Healthcare Trust
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aurora Cannabis has a beta of 0.417235, indicating that its share price is 58% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.365327, indicating that its share price is 63% less volatile than the broader market.

Aurora Cannabis currently has a consensus price target of C$6.20, indicating a potential upside of 4.38%. DRI Healthcare Trust has a consensus price target of C$25.60, indicating a potential upside of 41.20%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts plainly believe DRI Healthcare Trust is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

DRI Healthcare Trust has a net margin of 5.02% compared to Aurora Cannabis' net margin of -9.53%. DRI Healthcare Trust's return on equity of 2.06% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
DRI Healthcare Trust 5.02%2.06%4.22%

4.4% of Aurora Cannabis shares are held by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

DRI Healthcare Trust beats Aurora Cannabis on 12 of the 17 factors compared between the two stocks.

How does Aurora Cannabis compare to Knight Therapeutics?

Aurora Cannabis (TSE:ACB) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Aurora Cannabis has a beta of 0.417235, indicating that its share price is 58% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, indicating that its share price is 129% less volatile than the broader market.

Knight Therapeutics has a net margin of 2.72% compared to Aurora Cannabis' net margin of -9.53%. Knight Therapeutics' return on equity of 1.91% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
Knight Therapeutics 2.72%1.91%0.51%

Knight Therapeutics has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M1.17-C$44.16M-C$1.94N/A
Knight TherapeuticsC$547.31M1.81-C$30.73MC$0.1567.27

4.4% of Aurora Cannabis shares are held by institutional investors. Comparatively, 22.7% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Aurora Cannabis had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Aurora Cannabis and 1 mentions for Knight Therapeutics. Aurora Cannabis' average media sentiment score of 0.73 beat Knight Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Knight Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aurora Cannabis presently has a consensus target price of C$6.20, suggesting a potential upside of 4.38%. Knight Therapeutics has a consensus target price of C$9.50, suggesting a potential downside of 5.85%. Given Aurora Cannabis' higher probable upside, research analysts clearly believe Aurora Cannabis is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Knight Therapeutics beats Aurora Cannabis on 11 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to Hydropothecary?

Aurora Cannabis (TSE:ACB) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Aurora Cannabis had 3 more articles in the media than Hydropothecary. MarketBeat recorded 3 mentions for Aurora Cannabis and 0 mentions for Hydropothecary. Aurora Cannabis' average media sentiment score of 0.73 beat Hydropothecary's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
Aurora Cannabis Positive
Hydropothecary Neutral

Aurora Cannabis presently has a consensus target price of C$6.20, suggesting a potential upside of 4.38%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, research analysts clearly believe Aurora Cannabis is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Hydropothecary has lower revenue, but higher earnings than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M1.17-C$44.16M-C$1.94N/A
HydropothecaryN/AN/AN/AN/AN/A

4.4% of Aurora Cannabis shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hydropothecary has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. Hydropothecary's return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
Hydropothecary N/A N/A N/A

Summary

Aurora Cannabis beats Hydropothecary on 7 of the 10 factors compared between the two stocks.

How does Aurora Cannabis compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Aurora Cannabis has a net margin of -9.53% compared to Tilray Brands' net margin of -15.22%. Aurora Cannabis' return on equity of -5.21% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-15.22% -8.85% -1.41%
Aurora Cannabis -9.53%-5.21%-1.87%

Aurora Cannabis has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray BrandsC$915.45M0.89-C$183.24M-C$1.09N/A
Aurora CannabisC$314.07M1.17-C$44.16M-C$1.94N/A

Tilray Brands has a beta of 3.215277, indicating that its share price is 222% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.417235, indicating that its share price is 58% less volatile than the broader market.

Tilray Brands currently has a consensus target price of C$13.30, suggesting a potential upside of 129.31%. Aurora Cannabis has a consensus target price of C$6.20, suggesting a potential upside of 4.38%. Given Tilray Brands' higher probable upside, equities analysts clearly believe Tilray Brands is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Aurora Cannabis had 3 more articles in the media than Tilray Brands. MarketBeat recorded 3 mentions for Aurora Cannabis and 0 mentions for Tilray Brands. Aurora Cannabis' average media sentiment score of 0.73 beat Tilray Brands' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Overall Sentiment
Tilray Brands Neutral
Aurora Cannabis Positive

5.6% of Tilray Brands shares are owned by institutional investors. Comparatively, 4.4% of Aurora Cannabis shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aurora Cannabis beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to CanniMed Therapeutics?

Aurora Cannabis (TSE:ACB) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Aurora Cannabis had 3 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 3 mentions for Aurora Cannabis and 0 mentions for CanniMed Therapeutics. Aurora Cannabis' average media sentiment score of 0.73 beat CanniMed Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company Overall Sentiment
Aurora Cannabis Positive
CanniMed Therapeutics Neutral

CanniMed Therapeutics has lower revenue, but higher earnings than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$314.07M1.17-C$44.16M-C$1.94N/A
CanniMed TherapeuticsN/AN/AN/AN/AN/A

Aurora Cannabis currently has a consensus price target of C$6.20, indicating a potential upside of 4.38%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, research analysts plainly believe Aurora Cannabis is more favorable than CanniMed Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
CanniMed Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CanniMed Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -9.53%. CanniMed Therapeutics' return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-9.53% -5.21% -1.87%
CanniMed Therapeutics N/A N/A N/A

4.4% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aurora Cannabis beats CanniMed Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

Export
MetricAurora CannabisPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$379.86MC$12.60BC$7.31BC$12.84B
Dividend YieldN/A2.63%2.52%6.27%
P/E Ratio-3.06792.28274.0840.36
Price / Sales1.17862.22638.219.35
Price / Cash1.2588.6477.8082.29
Price / Book0.7010.5910.474.69
Net Income-C$44.16MC$2.81BC$3.49BC$299.09M
7 Day Performance10.20%-0.11%-0.67%0.01%
1 Month Performance8.59%-1.34%-3.17%-2.14%
1 Year Performance-17.50%2.86%15.14%20.17%

Aurora Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACB
Aurora Cannabis
1.237 of 5 stars		C$5.94
-1.0%		C$6.20
+4.4%		-14.4%C$379.86MC$314.07MN/A1,028
DHT.UN
DRI Healthcare Trust
2.8205 of 5 stars		C$18.42
+4.0%		C$25.60
+39.0%		+27.8%C$1.01BC$172.34MN/AN/A
GUD
Knight Therapeutics
0.3685 of 5 stars		C$10.29
+1.1%		C$9.50
-7.7%		+67.1%C$1.01BC$547.31M68.60830
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A
TLRY
Tilray Brands
1.2073 of 5 stars		C$5.96
+4.4%		C$13.30
+123.2%		-66.5%C$836.92MC$915.45MN/A3,595

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:ACB) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel